Agoracom Blog Home

Posts Tagged ‘Cannabis’

Marijuana Company of America $MCOA Reports 840% Year Over Year Revenue Growth for Year End 2018 $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:11 AM on Monday, April 15th, 2019

Company Cites Other Positive Financial Developments Which Include Decrease in SG&A Expenses and Significant Improvements on Balance Sheet

  • Total revenues of hempSMART™ products were $252,135 for the year ended Dec. 31, 2018, as compared to $26,830 from the prior year, representing a significant 840% increase year over year.
  • Gross profit for 2018 increased to $170,885, a 68% gross margin, compared to a gross margin of $12,536 for 2017, a 47% gross margin

Escondido, California–(April 15, 2019) – MARIJUANA COMPANY OF AMERICA INC. (OTCQB: MCOA) (“MCOA” or the “Company”), a vertically integrated hemp and cannabis corporation, is pleased to announce its financial results for the year ended Dec. 31, 2018, as reported in its annual report on Form 10-K.

2018 Financial Highlights

  • Total revenues of hempSMART™ products were $252,135 for the year ended Dec. 31, 2018, as compared to $26,830 from the prior year, representing a significant 840% increase year over year.
  • Net loss from operations decreased by 82% from $21,262,798 for the year ended Dec. 31, 2017, to $3,814,949 from the prior year.
  • Gross profit for 2018 increased to $170,885, a 68% gross margin, compared to a gross margin of $12,536 for 2017, a 47% gross margin.
  • SG&A expenses, including non-cash items and one-time transactional expenses, for 2018 decreased substantially by $17,292,265, or 81%, to $3,980,493, compared to $21,272,758 for the prior year.
  • For the year ended Dec. 31, 2018, the Company realized the following other one-time income items: Gain cancellation of debt of $1,500,000 and a gain of $560,000 from the change in value of its trading securities investment in Global Payout. The Company also settled a debt that resulted in a gain of $94,933.
  • Total assets increased by 70% from $1,129,958 in 2017 to $1,919,781 in 2018. This increase is due primarily to the increase in value of the Company’s investment in Global Payout’s stock, which is accounted for using the trading security method of accounting as well as an increase in cash and inventory.
  • Total liabilities decreased by 56% from $11,447,710 for 2017 to $5,053,887 for 2018. This decrease was largely due to the decrease in liabilities related to warrants and joint venture obligations.
  • Cash used by operating activities for 2018 was $2,385,349, compared to cash used for operating activities of $895,743 for 2017. Cash used by investing was $686,458, compared to $1,176,919 for 2017. Cash provided by financing activities for 2018 was $3,181,553, compared to $2,175,007 for 2017.

“I could not be prouder of the growth and accomplishments our company and team members achieved in 2018,” said Don Steinberg, founder, chairman and CEO of Marijuana Company of America. “Our industry experienced unprecedented legislative developments, including Canada going full adult use and the Farm Bill passing in the U.S. We are now better positioned than ever to be a leader in the cannabis industry. Not only did we expand our team, but we also launched our hempSMART sales in Europe. We expect to complete and announce our acquisition of a California marijuana manufacturing and distribution license shortly. Upon completion, this acquisition will allow us to capture additional market share, implementing a fully integrated cannabis model that includes cultivation of hemp, distribution and manufacturing of cannabis, and the retail delivery of our new Viva Buds brand.”

Jesus Quintero, CFO of Marijuana Company of America, said, “We are very pleased with the strong financial results of 2018. Our financial results were better than many other cannabis public companies in our sector, which are still in the development stage and not yet producing revenue. Marijuana Company of America, through our hempSMART brand, has experienced a dramatic increase in sales, most of which occurred in fourth quarter. This trend is continuing to grow in first and second quarter of 2019. We think our shareholders are going to be very satisfied with the execution of our highly aggressive growth and restructuring plans in 2019.”

Further details about the Company’s financial results are available in its annual report on Form 10K, which will be available in the investor relations section of the Company’s website at www.marijuanacompanyofamerica.com.

About Marijuana Company of America, Inc.

MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™” that target general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; and (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward-Looking Statements

This news release contains “forward-looking statements” that are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities, and words such as “anticipate,” “seek,” “intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

CLIENT FEATURE: $VERT.ca Vertical Exploration – Developing the St. Onge Wollastonite Project $TORR.ca $FA.ca

Posted by AGORACOM at 1:00 PM on Friday, April 12th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
https://upload.wikimedia.org/wikipedia/commons/thumb/8/80/WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg/220px-WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg
Wollastonite
  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calciuminosilicatemineral that may contain small amounts of iron, magnesium, and manganese substituting for calcium
  • Wollastonite is used primarily in ceramics, friction products (brakes and clutches), metalmaking, paint filler, and plastics.
  • Located close to Saguenay Port and year round shipping access

St-Onge-Wollastonite Deposit: Resource Classification

This image has an empty alt attribute; its file name is image-1-600x96.png

Utilizing Wollastonite as A Soil Additive

  • Vertical is researching the use of Wollastonite as a soil additive for optimizing marijuana growth
  • Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC
  • Phase Three trials measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium

Hub on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

Empower $EPW.ca Announces Ticker Symbol Change, New Website and Pending Company Name Change $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 3:46 PM on Wednesday, April 10th, 2019
  • Empower Clinics Inc. has changed its ticker symbol to CSE: CBDT
  • Proposes to change the Company name to CBD Therapeutics Corporation at the Company annual general meeting in June 2019.

VANCOUVER, April 10, 2019 – EMPOWER CLINICS INC. (CSE: EPW) (Frankfurt 8EC) (“Empower” or the “Company“), a growth oriented, diversified health and wellness company, announces that it has changed the Company’s ticker symbol on the Canadian Securities Exchange (the “CSE“) to CSE: CBDT. The Company also intends to seek shareholder approval for a change of name of the Company to CBD Therapeutics Corporation, and to launch a new Company website at www.empowerclinics.com

In recent weeks, the Company has been re-positioning its overall strategy to become a vertically integrated health and wellness company that connects to its 120,000 patients using a data driven focus to improve patients’ lives with products, technology and health systems.

The Company believes the change of name will allow its patients, customers, shareholders, partners, team members and the investment community to have a simple and clear understanding of the Company’s focus – a brand that is passionate about CBD based therapies, products and treatment options.

The Company’s new ticker symbol, CSE: CBDT, supports the new brand initiative and makes it easier for the Company’s followers in the investment community to associate the Company to its presence in the capital markets.

The Company has also launched a new website that is a better reflection of its health & wellness brand, providing users with a more functional and pleasant experience on desktop and mobile devices. The website will continue to evolve with new content and functionality being added over time, including educational sections, links to an e-commerce store to purchase CBD products, and a directory to the Company’s growing network of clinics.

The Company intends to change the domain name for the website in conjunction with the official name change, after approval of same at the Company’s next annual general and special meeting of shareholders.

“Evolving the business model and brand of the Company has been an imperative initiative for me on behalf of our shareholders, and the announcement of the Company’s ticker symbol change and proposed name change reflects our path going forward,” stated Steven McAuley, Empower’s Chairman and CEO. “We believe the new website will allow us to drive traffic with confidence, knowing our online presence tells the story of our brand and provides users access to our extensive knowledge-base, product offerings and world-class physicians throughout our network of clinics.”

ABOUT EMPOWER

Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding the Company’s proposed name change; new website; and the expected benefits of same for the Company and its stakeholders. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the proposed acquisitions and partnerships, including that: the name change may not be approved by the Company’s shareholders or may not be completed; that the website may not operate as expected; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2019/10/c7790.html

Investors: Steve Low, Boom Capital Markets, 647-620-5101; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019

North Bud Farms Inc. $NBUD.ca – Edible Arrangements: The Global Cannabis Edibles Market $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:53 AM on Tuesday, April 2nd, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information

NBUD: CSE

—————

Edible Arrangements: The Global Cannabis Edibles Market

  • The global cannabis edibles market is one of the most promising segments of the overall industry, presenting a world of opportunity for cannabis edibles companies to set themselves apart with unique and appealing products.
  • For cannabis connoisseurs, cannabis edibles have always been an alluring proposition.

For cannabis connoisseurs, cannabis edibles have always been an alluring proposition. Take something you already enjoy, and add it to something delicious. What’s not to like? The classic “special brownie” and the famous “space cakes” that have been enjoyed at Amsterdam coffee shops for decades are only just the tip of the edibles iceberg. Today, cannabis is being added to candy, artisanal baked goods, coffee, jerky, pizza, upscale cuisine and so much more, meaning the possibilities are endless for the global cannabis edibles market.

It’s no surprise that the Canadian legal cannabis industry is hungrily eyeing cannabis edibles as they promise to account for a huge portion of the overall cannabis market as soon as Health Canada allows it. In the meantime, however, this highly promising market segment faces some significant regulatory challenges. That won’t stop companies from taking an interest in edibles, as they already make up a huge portion of the market in legal jurisdictions where they are allowed, such as California and Nevada.

Edibles to take cannabis market by storm

The consumer appeal of edibles is obvious. The sheer amount of variability creates countless possibilities for cannabis companies looking to make their products stand out. Edibles can be tailored to any type of cannabis consumer, from high-end dark chocolates served at posh dinner parties to gummy candies enjoyed before a rock concert. It’s easy to make edible cannabis products eye catching and appealing. For newcomers trying cannabis for the first time after legalization, edibles may provide a less intimidating entry point than smoking or vaping. And medical users often appreciate the stronger and longer-lasting effect of orally ingested cannabis.

An October 2018 report by ArcView Market Research and BDS Analytics projects the North American cannabis edibles market to hit more than $4.1 billion by 2022. According to the report, food and drink products accounted for approximately 11.4 percent of total cannabis spending in Canada and the United States in 2017. As the cannabis market matures and develops, and as edible products return to dispensary shelves in Canada, classic dried cannabis flower is expected to steadily lose market share to edibles and extracts.

Regulatory challenges and solutions

Right now in Canada, though, the more immediate future of the cannabis edibles market is less certain. Edibles were not included in the first wave of cannabis legalization that took place in October 2018, with Health Canada opting to conduct further study and consultation before rolling out regulatory rules by October 2019. This put a wrench in the gears for the hundreds of cannabis companies that had made edibles a key part of their initial business strategy. In early 2019, Health Canada began a two-month public consultation period as part of the process of determining the edibles regulatory scheme. By all accounts, the restrictions are likely to be heavy. Chief among the rules will be restrictions on potency and mandates on accurate potency labeling.

The concerns over potency and accurate labeling aren’t entirely unwarranted. Cannabis edibles have always been tricky in the way they hit the user. Cannabis ingested through the digestive system can take an hour or more to for the user to notice the effect, and inexperienced users have commonly been known to make the rookie mistake of taking more under the belief that they haven’t taken a high enough dosage. Due to the intense nature of edible products, the appeal of edibles to inexperienced cannabis users in particular can be a recipe for disaster. Excessive dosage of cannabis is not highly dangerous in that it will not cause poisoning or other health emergencies, but cannabis-related panic attacks can still present a risk.

This is why cannabis companies that plan on making edibles a significant part of their business model have dedicated considerable resources to developing precision dosing technology. The challenge stems from the fact that the rate in which cannabis breaks down as it enters the bloodstream varies significantly based on a number of factors, including the specific physiology of the consumer.

Recent years have seen the development of tools for manipulating cannabis at the molecular level for greater bioavailability, allowing edibles manufacturers to provide a more predictable product for easier regulatory compliance and greater consumer trust.

Regulators have been placing a range of other regulatory hurdles in the way of the edibles market. Health Canada is expected to enforce tight restrictions on edibles packaging, limiting the use of colorful graphics and other eye-catching elements largely with the intent of limiting the products’ appeal to children. Packaging will also need to be child resistant. Regulators in various jurisdictions have often restricted potency, with Health Canada expected to limit products to 10 milligrams of THC per dose. Similarly, California has focused its regulations around keeping cannabis edibles out of the hands of children with a universal cannabis product symbol, a government warning, child-proof packaging and clear labeling for potency and recommended dosage.

Takeaway

Not every cannabis consumer is particularly interested in smoking or vaping, but everyone is interested in tasty treats. Meeting regulatory hurdles for dosing and keeping products out of the hands of children has been a challenge, but these challenges hardly reduce the potential of what promises to be, and in many jurisdictions already is, one of the primary market segments of the cannabis industry.

Source: https://investingnews.com/innspired/global-cannabis-edibles-market/

CLIENT FEATURE: $VERT.ca Vertical Exploration – Developing the St. Onge Wollastonite Project $TORR.ca $FA.ca

Posted by AGORACOM at 12:20 PM on Friday, March 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
https://upload.wikimedia.org/wikipedia/commons/thumb/8/80/WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg/220px-WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg

WOLLASTONITE

  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calcium inosilicate mineral that may contain small amounts of iron, magnesium, and manganese substituting for calcium
  • Wollastonite is used primarily in ceramics, friction products (brakes and clutches), metalmaking, paint filler, and plastics.
  • Located close to Saguenay Port and year round shipping access

St-Onge-Wollastonite Deposit: Resource Classification

Utilizing Wollastonite as A Soil Additive

  • Vertical is researching the use of Wollastonite as a soil additive for optimizing marijuana growth
  • Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC
  • Phase Three trials measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium

Hub on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

$APPB Applied Biosciences Announces Partnership with Boxing Heavyweight Champion Shannon Briggs $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM at 10:38 AM on Wednesday, March 20th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Signed a partnership agreement with Shannon “the Cannon” Briggs, the former heavyweight boxing champion and world record-holder for the most first round knockouts
  • Briggs and the Company will work together to formulate a line of athlete-focused cannabidiol (“CBD”) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand.

LOS ANGELES, March 20, 2019 (GLOBE NEWSWIRE) — Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and pet health industries, announced that has signed a partnership agreement with Shannon “the Cannon” Briggs, the former heavyweight boxing champion and world record-holder for the most first round knockouts. 

Through this new partnership, Briggs and the Company will work together to formulate a line of athlete-focused cannabidiol (“CBD”) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand.

Additionally, Briggs and the Company will collaborate on an awareness campaign to help educate athletes around the world about the potential benefits of using CBD for pain management, relaxation, decreasing anxiety and improving sleep quality.  Briggs hopes to educate the public on the potential benefits of using CBD to help decrease dependence on opioids.

“I have partnered with Applied BioSciences to develop and market Champ Organics because their products are made with the highest quality ingredients and all-natural CBD.  I am a firm believer in the benefits that CBD delivers for joint pain and headaches. Since I have incorporated CBD to my daily supplements, I have been surprised by the positive impact it has had on my overall quality of life.”  commented Shannon Briggs

“Every day, roughly 130 Americans die from opioid overdoses1,” noted Briggs. “Meanwhile, a recent study2 in the Journal of the American Medical Association showed that in states where people could legally use cannabis, the number of filled opioid prescriptions dropped significantly, and there were lower rates of opioid overdose and death.”

“The all-natural formulations of Applied Biosciences’ Remedi CBD products attracted Briggs to our Company,” commented Chris Bridges, President and Director of Applied Biosciences. “Our Company’s aligned mission to end the country’s opioid epidemic was what made him choose Applied in the end.  This partnership will allow us to expand into a new vertical and additional distribution channels globally.”

1:https://www.cdc.gov/drugoverdose/epidemic/index.html

2:https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2676999

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

About Shannon Briggs
Born in Brooklyn, New York, Shannon “the Cannon” Briggs was an American professional boxer for 20 years, having twice won the title of world heavyweight champion, having held the lineal title from 1997 to 1998, and the World Boxing Organization title from 2006 to 2007.

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website:www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

$VERT Vertical Exploration Completes Successful Drilling Program at St. Onge Wollastonite Deposit $TORR $FA.ca

Posted by AGORACOM at 8:46 AM on Monday, March 18th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
  • Twenty-three (23) drill holes totaling 1,784.0 metres were completed in less than two weeks of drilling (see Figure 1 & Table 1).
  • Twenty (20) drill holes intersected high-grade wollastonite zones, confirming excellent continuity and correlation with the thickly mineralized zones intersected by previously reported historical drill holes.
  • Sixteen (16) drill holes intersected high-grade wollastonite zones right up until the end of the hole, which are all open at depth.
  • A total of 1,107.5 meters of high-grade wollastonite mineralized core length was intersected, representing approximately 62% of all drilled core length.

VANCOUVER, BC / ACCESSWIRE / March 18, 2019 / VERTICAL EXPLORATION INC. (TSX-V: VERT) (“Vertical” or “the Company”) is pleased to announce that it has completed a successful diamond drilling and sampling program on its advanced stage St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.

The primary goal of the 2019 drilling program, which consisted of seven (7) drilling sections (see Figure 1, Sections A-G), was to establish an additional measured mineral resource of approximately 5 million tonnes of crude wollastonite. The pit constrained mineral resources at the St-Onge Wollastonite deposit, as previously reported in the Company’s August 2, 2018 news release, comprises an NI 43-101 compliant resources totaling 14 million tonnes at 36.61% Wollastonite in the measured and indicated class using a cut-off grade of 30% Wollastonite (7.1 million tonnes at 36.20% in measured and 6.9 million tonnes at 37.04% in indicated), and 17.9 million tonnes at 40.25% in the inferred class (rounded numbers). The NI 43-101 Technical Report was prepared by GoldMinds Geoservices Inc. (‘GMG’).

HIGHLIGHTS OF THE 2019 DRILLING CAMPAIGN

  • Twenty-three (23) drill holes totaling 1,784.0 metres were completed in less than two weeks of drilling (see Figure 1 & Table 1).
  • Twenty (20) drill holes intersected high-grade wollastonite zones, confirming excellent continuity and correlation with the thickly mineralized zones intersected by previously reported historical drill holes.
  • Sixteen (16) drill holes intersected high-grade wollastonite zones right up until the end of the hole, which are all open at depth.
  • A total of 1,107.5 meters of high-grade wollastonite mineralized core length was intersected, representing approximately 62% of all drilled core length.

In total, nine hundred thirteen (913) drill core samples of approximately 1.5 metres in length, including samples ranging from less than one 1.0 metre in length and up to a maximum of 2.5 metres in length, were collected for laboratory assaying. Eighty-one (81) of the 913 drill core samples were quality assurance/quality control (QA/QC) samples, including mineralized certified samples, blank samples and duplicate samples.

Peter P. Swistak, President and CEO of Vertical Exploration, commented: ”I am very pleased with the speed of completion and overall success of this 2019 drilling program. The mineral data obtained from the program will now allow the Company to further update its NI 43-101 Technical Report and continue to aggressively move forward with its plans to begin the quarry permitting process on its St-Onge-Wollastonite Deposit.”

Complete drilling results for the 23 hole program will be announced when received.

The diamond drilling program has been supervised by Jean-Paul Barrette P. Geo., a qualified person under National Instrument 43-101 contracted by Magnor Exploration Inc., and responsible for reviewing and approving the technical contents of this press release as they pertain to the St-Onge-Wollastonite property.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge-Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD

Peter P. Swistak, President

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

Table 1: List of 2019 drill holes and wollastonite skarn intervals intersected

Figure 1: Location of historical and 2019 drill hole collars

SOURCE: Vertical Exploration Inc.

CLIENT FEATURE: Applied Biosciences $APPB Investment in JUUL Labs Paying Dividends for Shareholders $HTIM $JUUL $WMD

Posted by AGORACOM at 10:19 AM on Wednesday, February 6th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Received a capital distribution of approximately $186,000 from its investment in JUUL Labs, Inc. (JUUL)
  • The investment remains on the balance sheet under Equity Investments, the company has begun a strategic review of options for the remaining equity stake. 
  • Altria Group Inc. (NYSE: MO) on December 20, 2018 announced it had invested $12.8bn in vaping company Juul Labs, a 35% stake valuing JUUL at $38 billion.
  • APPB also recently acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company with proven revenues
  • Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00
  • APPB has a market cap of $15m US & 10m S/O

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website:www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Link to AppliedBioSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp.

Applied Biosciences $APPB Receives Distribution from Investment in JUUL Labs $HTIM $WMD $JUUL

Posted by AGORACOM at 11:28 AM on Tuesday, February 5th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Received a capital distribution of approximately $186,000 from its investment in JUUL Labs
  • Altria Group Inc. (NYSE: MO) invested $12.8bn in vaping company Juul Labs, a (35% stake) valuing JUUL at $38 billion
  • The global e-cig and vaporizer market is one of the fastest growing consumer markets and has been recently valued at $9.0 billion and expected to grow at a CAGR of 23.6% and reach $49 billion by the end of 2024
  • APPB has a market cap of $15m US & 10m S/O

LOS ANGELES, Feb. 05, 2019 (GLOBE NEWSWIRE) — Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that has received a capital distribution of approximately $186,000 from its investment in JUUL Labs, Inc. (JUUL).   The company has made strategic investments in select companies they believed to be innovators in the consumer space.  The investment remains on the balance sheet under Equity Investments, but the company has begun a strategic review of options for the remaining equity stake. 

Altria Group Inc. (NYSE: MO) on December 20, 2018 announced it had invested $12.8bn in vaping company Juul Labs, a 35% stake valuing JUUL at $38 billion.  Howard Willard, Altria’s CEO said in a statement that the move was an effort to “prepare for a future where adult smokers overwhelmingly choose non-combustible products over cigarettes.” 

JUUL has become a success story and one of the fastest growing companies in the US, growing revenue to over $1 billion in a few short years.  Their brand has become synonymous with vaping and the e-cigarette market. 

The global e-cig and vaporizer market is one of the fastest growing consumer markets and has been recently valued at $9.0 billion and expected to grow at a CAGR of 23.6% and reach $49 billion by the end of 2024, according to Research Nestor (www.researchnester.com).

The company continues to make select investments in companies that can help shape the product roadmap and development of new products and potential partnerships.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website:www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Vertical Exploration $VERT.ca Announces Wollastonite Research and Development Results

Posted by AGORACOM at 9:00 AM on Tuesday, February 5th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
  • Successful completion of Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive
  • Phase Three trials BCBD measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • Optimal results occurred with an admixture rate of 10% to 15% Wollastonite to the growth medium

VANCOUVER, BC / February 5, 2019 / VERTICAL EXPLORATION INC. (TSX-V: VERT) (“Vertical” or the Company”) is pleased to announce the successful completion of Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC. The positive Phase Three trials build on the success of Phase Two Trials, which included samples of marijuana grown with 15% wollastonite from the Company’s St. Onge project being entered in an international growers’ competition, winning first place overall for Best Flower at the August 2018 Kootenay Cannabis Cup in Cranbrook, BC. (see October 2, 2018 news release.)

In the Phase Three trials BCBD measured and recorded significant improvements in root mass, powdery mildew control and pest elimination. In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium. Most notably, powdery mildew, the most common fungal blight to affect Cannabis sativa, was virtually undetectable with wollastonite admixture above 10%. An admixture above 10% wollastonite also correlated with sharp reductions in the presence of thrips and fungus gnats, insect pests with a sub-soil life phase in which the wollastonite crystals lacerate and impale their soft bodies. At a microscopic level, wollastonite’s needle-like structure penetrates soft-bodied insect larvae and pupae, interrupting the life cycle without the use of pesticides. Wollastonite’s unique properties also allow it to break down into calcium, magnesium and silicon in a highly bio-available form that balances soil PH throughout the growth cycle – this allows the cannabis plants to uptake silicic acid and promotes strong cell walls that better resist insect feeding and spore penetration, supporting increased growth and elevated product yields.

“We recorded a dramatic elevation of overall health among plants grown with wollastonite,” stated Matthew Harvey, CEO of BCBD. “The wollastonite group produced consistently low levels of powdery mildew — little to none – appearing later in the growth cycle. Roots, meanwhile, showed extreme vigour, growing dense and white with no sign of yellowing. Root health indicates a plant’s ability to resist disease and to support high yields of high-quality of finished marijuana.

According to Mr. Harvey the findings of the Phase Three BCBD wollastonite study indicate a major financial implication for the cannabis industry, where a trend towards cultivation of expansive plant canopies creates a powerful incentive for effective and efficient methods of crop protection and production.

As Mr. Harvey explained, “Large-scale cultivators need every tool at their disposal to improve plant health and avoid crop losses – a 10% to 20% loss in crop production due to a preventable outbreak of a destructive fungal pathogen can equate to millions of dollars of lost product. Companies that take crop protection seriously are looking for cost-effective soil additives that not only nourish plants but build resilience against the pests and pathogens that threaten profits. Our findings show wollastonite to be a critical tool for both cannabis crop protection and top-end production in a market where quality is of vital importance. It is no longer acceptable to spray fungicides on marijuana: natural prevention is the key and wollastonite is the answer.

Vertical’s CEO Peter Swistak commented: “We are very excited by these excellent Phase Three results which prove that wollastonite is a very appealing natural growing additive for the cannabis industry because it couples crop protection with product improvement, resulting in a more natural and healthier product for consumers.”

With the highly successful completion of these Phase Three cannabis trials at BCBD, Vertical is now moving aggressively forward with its plans to test market its high-quality St. Onge wollastonite to both micro-producers and large-scale cannabis companies. Vertical believes that the cannabis industry offers significant revenue potential for the company and anticipates providing further updates on its cannabis testing and marketing efforts in the near future.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD
Peter P. Swistak, President

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).

SOURCE: Vertical Exploration Inc.